Serological Response to Vaccination after Autologous Transplantation for Multiple Myeloma Is Associated with Improved Progression-Free and Overall Survival.

[1]  I. Karpov,et al.  Clinical efficacy of pneumococcal vaccination in multiple myeloma patients on novel agents: Results of a prospective clinical study. , 2020, Vaccine.

[2]  R. Pfeiffer,et al.  Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. , 2019, JAMA oncology.

[3]  P. Ljungman,et al.  Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). , 2019, The Lancet. Infectious diseases.

[4]  Thomas S. Watkins,et al.  Bone marrow transplantation generates T cell–dependent control of myeloma in mice , 2018, The Journal of clinical investigation.

[5]  B. Barlogie,et al.  Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. , 2018, Blood advances.

[6]  G. Morgan,et al.  Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials , 2018, Leukemia.

[7]  H. Valdez,et al.  T‐cell–mediated immune response to pneumococcal conjugate vaccine (PCV‐13) and tetanus toxoid vaccine in patients with moderate‐to‐severe psoriasis during tofacitinib treatment , 2018, Journal of the American Academy of Dermatology.

[8]  J. Laubach,et al.  Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation , 2018, Bone Marrow Transplantation.

[9]  M. Perales,et al.  Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  A. Vangsted,et al.  Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population , 2017, PloS one.

[11]  P. Wallace,et al.  Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT. , 2017, Blood advances.

[12]  N. Puig,et al.  Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma , 2017, Haematologica.

[13]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[14]  G. Wertheim,et al.  Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. , 2016, Blood.

[15]  H. Goldschmidt,et al.  Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma , 2015, Haematologica.

[16]  M. Bornhäuser,et al.  Multiple myeloma , 2015, The Lancet.

[17]  A. Bousvaros,et al.  2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  M. Pérez‐Andrés,et al.  Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry , 2013, Haematologica.

[19]  J. Orange,et al.  Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. , 2012, The Journal of allergy and clinical immunology.

[20]  S. Rutella,et al.  Targeting Multiple-Myeloma-Induced Immune Dysfunction to Improve Immunotherapy Outcomes , 2012, Clinical & developmental immunology.

[21]  M. Aljurf,et al.  Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation , 2012, Bone Marrow Transplantation.

[22]  C. Huff,et al.  Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses , 2012, Clinical Cancer Research.

[23]  M. Aljurf,et al.  Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation , 2012, Revista brasileira de hematologia e hemoterapia.

[24]  H. Einsele,et al.  Vaccination of hematopoietic cell transplant recipients , 2009, Bone Marrow Transplantation.

[25]  Hermann Einsele,et al.  Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective , 2009, Biology of Blood and Marrow Transplantation.

[26]  G. Rijkers,et al.  Vaccination responses and lymphocyte subsets after autologous stem cell transplantation. , 2007, Vaccine.

[27]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Guinan,et al.  Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.